Valganciclovir
- Generic Name
- Valganciclovir
- Brand Names
- Valcyte
- Drug Type
- Small Molecule
- Chemical Formula
- C14H22N6O5
- CAS Number
- 175865-60-8
- Unique Ingredient Identifier
- GCU97FKN3R
- Background
Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases.
- Indication
Valganciclovir is an antiviral medication used for the treatment of cytomegalovirus infections.
- Associated Conditions
- Cytomegalovirus (CMV) Infections, Cytomegalovirus Retinitis
- Associated Therapies
- -
Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2013-07-23
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 39
- Registration Number
- NCT00241345
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
MICI-CMV:Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by Cytomegalovirus
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2009-04-03
- Lead Sponsor
- University Hospital, Grenoble
- Target Recruit Count
- 40
- Registration Number
- NCT00237653
- Locations
- 🇫🇷
Gastroenterology Department - University Hospital of Grenoble, Grenoble, France
Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation
- First Posted Date
- 2005-09-28
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Duke University
- Target Recruit Count
- 136
- Registration Number
- NCT00227370
- Locations
- 🇺🇸
DukeUMC, Durham, North Carolina, United States
Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT00217503
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
Suppression of Oral HHV8 Shedding With Valganciclovir
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2008-01-10
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 32
- Registration Number
- NCT00194467
- Locations
- 🇺🇸
University of Washington Virology Research Clinic, Seattle, Washington, United States
Pharmacokinetics of Mmf and Valganciclovir
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2016-05-25
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 16
- Registration Number
- NCT00189150
- Locations
- 🇺🇸
University of Michigan Hospital, Ann Arbor, Michigan, United States
Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2016-11-29
- Target Recruit Count
- 130
- Registration Number
- NCT00141037
- Locations
- 🇺🇸
UCLA - Department of Pediatrics, Division of Nephrology, Los Angeles, California, United States
🇺🇸Children's Hospital Boston - Division of Nephrology, Boston, Massachusetts, United States
🇺🇸Children's Hospital of New Orleans-Department of Pediatric Nephrology, New Orleans, Louisiana, United States
Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma
- First Posted Date
- 2004-11-10
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT00096538
- Locations
- 🇺🇸
Memorial Sloan - Kettering Cancer Center, New York, New York, United States
🇺🇸New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States
🇺🇸Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
- Conditions
- Interventions
- First Posted Date
- 2004-09-22
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 75
- Registration Number
- NCT00092222
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-05-17
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 184
- Registration Number
- NCT00016068
- Locations
- 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸University of Florida Shands Cancer Center, Gainesville, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.